A company backed by global private equity firm Permira, has agreed to acquire Neuraxpharm, a European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners. Financial details of the transaction have not been disclosed.   With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercialises value-added medicines and consumer healthcare products for chronic patients suffering from neurological and psychiatric disorders including Epilepsy, Parkinson’s, Alzheimer’s, Depression and Psychosis. With one of the broadest and most diversified product portfolios in the market, its strong medical reputation and

ARQIS has advised AVS Verkehrssicherung on the acquisition of SRV Verkehrstechnik.SRV was founded in 1990 to meet the high demand for infrastructure services in the former East German states. The professional application of white or yellow road markings in paint, hot or cold plastic is the specialty of SRV. Services in the field of traffic safety and the necessary road equipment complete the portfolio.   AVS Verkehrssicherung, headquartered in Leverkusen, is a leading specialist provider of traffic safety services in Germany and Europe. The company is represented at over 25 locations in Germany and internationally at more than 10 locations

AMP Capital has agreed to acquire a majority stake in VX Fiber, an international infra tech fibre business headquartered in Sweden, on behalf of investors in its infrastructure equity strategy. VX Fiber has existing operations in South Africa and the UK and is targeting an advanced pipeline of opportunities in the UK, Belgium, Austria and Germany. VX Fiber designs, builds and operates full fibre FTTP (Fibre-To-The-Premise) open access networks globally and has developed its own proprietary software platform which it operates on third parties’ passive fibre infrastructure as fibre operator. The entire network is remotely run through a network operations centre

Odyssey Investment Partners (Odyssey) is to acquire ProPharma Group from Linden Capital Partners. Financial terms of the transaction have not been disclosed. Founded in 2001, ProPharma Group is a leading provider of regulatory and compliance services to pharmaceutical, biotechnology and medical device customers. The Company’s primary service offerings include regulatory affairs, life science consulting, pharmacovigilance and medical information services. ProPharma Group partners with its clients from early concept development through each clinical phase, product launch, and commercialisation to help ensure regulatory expectations are met, business goals are achieved, and patient health and safety is improved. ProPharma Group is headquartered in Overland